Cryolipolysis is considered a safe, low-risk procedure for reducing small pockets of fat. It’s FDA-cleared, noninvasive, and causes no permanent damage to skin, nerves, or surrounding tissue in the vast majority of cases. That said, “safe” doesn’t mean “zero risk.” There are temporary side effects nearly everyone experiences, a rare but real complication worth knowing about, and certain medical conditions that rule out the procedure entirely.
How Fat Freezing Works Without Harming Other Tissue
The core reason cryolipolysis is safe comes down to biology: fat cells are more vulnerable to cold than skin, muscle, or nerve cells. The device cools the treatment area to between negative 3°C and 6°C, a range cold enough to crystallize the fats inside fat cells but not cold enough to cause frostbite or permanent tissue damage. Once the fat crystals form, the affected cells go through a process of natural cell death over the following weeks. Your body’s immune system gradually clears those dead cells, and the fat layer in the treated area shrinks.
This selectivity is what separates cryolipolysis from more aggressive procedures. The skin, blood vessels, and nerves in the area stay intact because they can tolerate that temperature range without injury. It’s also why the procedure doesn’t require anesthesia, incisions, or any recovery downtime.
FDA Clearance and Approved Treatment Areas
The CoolSculpting device, which is the most widely used cryolipolysis system, was first cleared by the FDA for the flanks (love handles) in 2010, then the abdomen, and later the thighs in 2014. Additional clearances have since been granted for areas like the upper arms, under the chin, the bra line, and the area beneath the buttocks. The clearance applies to people with a BMI of 30 or less, meaning the procedure is designed for spot reduction of stubborn fat rather than overall weight loss.
Common Side Effects and How Long They Last
Almost everyone who gets cryolipolysis experiences some temporary side effects at the treatment site. These include redness, swelling, bruising, skin sensitivity, stinging or tingling, and general achiness or soreness. For most people, these effects clear up within a few days to a few weeks.
Numbness is especially common. One study found that about 66% of patients had reduced skin sensation in the treated area afterward. This typically resolves gradually, with full sensation returning by roughly 56 days (about two months) after treatment. The numbness isn’t a sign of nerve damage. It reflects a temporary effect on the superficial sensory nerves in the skin, and studies using detailed nerve testing have confirmed that recovery is thorough.
The One Complication Worth Understanding
The most notable serious risk of cryolipolysis is a condition called paradoxical adipose hyperplasia, or PAH. Instead of shrinking, the fat in the treated area grows larger, forming a firm, painless mass that matches the shape of the applicator. It’s the opposite of what the procedure is supposed to do, and it doesn’t resolve on its own. Correcting PAH typically requires liposuction.
The good news is that PAH is rare. A large review of over 8,600 treatment cycles across eight clinics in Canada found incidence rates between 0.05% and 0.39%, depending on which generation of device was used. With newer models of the CoolSculpting system, the rate dropped by more than 75%, landing at roughly 1 in 2,000 treatment cycles. The device manufacturer reports its own figure at about 1 in 4,000 cycles. Either way, the risk is low, but it’s not zero, and anyone considering the procedure should be aware of it before going in.
PAH tends to develop within two to five months after treatment. Researchers haven’t yet identified clear predictive factors for who is most likely to develop it, so it remains somewhat unpredictable at the individual level.
Who Should Not Get Cryolipolysis
Certain medical conditions make cryolipolysis genuinely unsafe. The procedure is contraindicated for people with cryoglobulinemia (a condition where abnormal proteins in the blood clump together in cold temperatures), cold agglutinin disease (where red blood cells clump and break down in response to cold), and paroxysmal cold hemoglobinuria (a rare condition causing red blood cell destruction after cold exposure). For these individuals, applying sustained cold to the body could trigger a dangerous systemic reaction.
People with cold-sensitive conditions like Raynaud’s phenomenon or cold urticaria (hives triggered by cold) should approach the procedure with caution, and those with known neurologic diseases may also face elevated risk. If you have any condition that flares up in cold environments, it’s worth discussing this specifically with the provider before treatment.
Why Your Provider Matters
Cryolipolysis is noninvasive, but the quality of your outcome still depends heavily on who performs it. Improper applicator placement, poor patient screening, or using the procedure on someone who isn’t a good candidate can increase the risk of complications or simply waste your money on a treatment that won’t produce visible results.
There’s no single universal certification required for performing cryolipolysis, and regulations vary by state and country. In general, look for providers who operate under the supervision of a board-certified dermatologist or plastic surgeon, have specific training on the device they’re using, and conduct a thorough screening for contraindications before agreeing to treat you. Clinics that skip the consultation or let you walk in for same-day treatment without a health history review are a red flag.
What the Long-Term Data Shows (and Doesn’t)
Short-term safety data for cryolipolysis is strong. Studies consistently show that side effects are temporary and that skin, nerve, and muscle tissue recover fully. What’s less established is the very long-term picture. Reliable studies tracking outcomes five to ten years after treatment are still lacking, and researchers have noted this gap. There’s no evidence of delayed harm emerging years later, but the absence of long-term studies means that conclusion is based on a relatively short track record rather than decades of follow-up data. For a procedure that’s been commercially available since 2010, this is expected, but it’s an honest limitation of the current evidence.